Molecular Biomarkers for the Evaluation of Colorectal Cancer
Open Access
- 6 February 2017
- journal article
- practice guideline
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 147 (3), 221-260
- https://doi.org/10.1093/ajcp/aqw209
Abstract
Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.Keywords
Funding Information
- NIH
This publication has 132 references indexed in Scilit:
- The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-AnalysisPLOS ONE, 2013
- Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumabCancer Medicine, 2013
- Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysisInternational Journal of Cancer, 2013
- Quality Assessment and Correlation of Microsatellite Instability and Immunohistochemical Markers among Population- and Clinic-Based Colorectal Tumors: Results from the Colon Cancer Family RegistryThe Journal of Molecular Diagnostics, 2011
- Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAFThe Journal of Molecular Diagnostics, 2011
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximabEuropean Journal of Cancer, 2010
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- The Catalogue of Somatic Mutations in Cancer (COSMIC)Current Protocols in Human Genetics, 2008
- Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studiesThe Lancet, 2007